PREVENTION OF NEUROMOTOR DEFICITS WITH CHELATION THERAPY

描述(改编自申请人的摘要)：以前的研究有 表明琥珀酸是铅的软组织螯合剂；因此，潜在的 神经行为的健康益处是可以预期的。然而，大多数 已发表的研究将注意力集中在斯克里默的能力上。 降低血铅水平，但不评估其对神经行为的影响 健康。拟议的横断面研究旨在评估罚款 运动和粗大运动的熟练程度以及姿势平衡和步态 200名儿童[来自辛辛那提临床中心，治疗铅中毒 儿童(TLC)]目前在随机双盲中活跃 临床试验旨在评估铅螯合的效果，使用 毒品代替品。在拟议的研究中，我们将评估姿势平衡 TLC儿童术后步态和精细运动和粗大运动发育 完成他们的继发性或安慰剂计划和TLC随访期。 姿势平衡和步态以及精细和粗大运动评估将是 使用已被我们超过13个人使用的既定技术执行 辛辛那提领导计划项目(LPP)队列中的年份。姿势 平衡和步态将使用基于微处理器的力量平台进行评估 系统以及测试协议，该测试协议间接评估 与姿势平衡有关的各种生理系统。精致马达 并将使用全面的 Bruininks-Oserestsky运动能力测试(BOTMP)测试电池。这个 琥珀酸类药物的TLC临床试验主要集中在全球措施上 认知发展。对运动发展的总体和总体评估 不强调精细运动球、姿势平衡和运动。 因此，这项研究将对我们理解 螯合疗法的发育效益及其他减少的措施 正在考虑的暴露范围内的铅。我们出版的 辛辛那提LPP队列的研究结果与拟议的运动开发 测量仪器(BOTMP)、姿势平衡试验和运动试验 表明这些测量技术是敏感的，与 认知测量相对不受社会经济辅助因素的影响。 因此，该项目对于进一步加深对中国的认识具有重要意义。 琥珀酸类药物在姿势平衡发育方面的临床益处， 发育中的运动结果与精细运动和粗大运动功能 社会经济弱势人群的中枢神经系统。

DESCRIPTION (adapted from the applicant's abstract): Previous studies have shown that succimer is a soft tissue chelator of lead; therefore, potential neurobehavioral health benefits may be expected. However, most of the published studies focused their attention toward succimer's ability to reduce blood lead level without evaluating its impact on neurobehavioral health. The proposed cross-sectional study is designed to evaluate the fine motor and gross motor proficiency as well as postural balance and gait in 200 children [from the Cincinnati Clinical Center for Treatment of Lead in Children (TLC)] who are currently active in a randomized double blind clinical trial designed to assess the effects of lead chelation using the drug succimer. In the proposed study, we will be assessing postural balance and gait and fine and gross motor development after the TLC children have completed their succimer or placebo program and the TLC follow-up period. The postural balance and gait and fine and gross motor assessments will be carried out with established techniques which have been used by us over 13 years on the Cincinnati Lead Program Project (LPP) cohort. The postural balance and gait will be assessed with a microprocessor-based force platform system along with a test protocol which indirectly assesses the roles of various physiological systems relevant for postural balance. The fine motor and gross motor assessments will be carried out using the comprehensive Bruininks-Oserestsky Test of Motor Proficiency (BOTMP) test battery. The TLC clinical trial of succimer is focused mainly on global measures of cognitive development. Assessments of motor development in the gross and fine motor spheres, postural balance and locomotion are not emphasized. Thus, this study will make a unique contribution to our understanding of the developmental benefits of chelation therapy and other measures to reduce lead in the range of exposures that are being considered. Our published findings from Cincinnati LPP cohort with the proposed motor development measurement instrument (BOTMP), postural balance test and locomotion test indicate that these measurement techniques are sensitive and, compared to cognitive measures are relatively uninfluenced by socioeconomic cofactors. Thus, the project has significance for furthering out understanding of the clinical benefits of succimer on developmental aspects of postural balance, locomotional outcomes and fine and gross motor functions in the developing central nervous system in socioeconomically disadvantaged populations.